A Depo-Provera meningioma lawsuit seeks compensation for women who developed a meningioma after using the contraceptive injection. This article covers eligibility, evidence, and what to expect from the process.
Women who have used Depo-Provera, an injectable contraceptive medication, and later received a diagnosis of meningioma may have legal options. Meningiomas are brain tumors that form in the protective membranes surrounding the brain and spinal cord. Recent scientific research has identified a potential link between long-term use of Depo-Provera and the development of these tumors.
The Depo-Provera meningioma lawsuit represents a developing area of pharmaceutical litigation where women are seeking compensation for injuries they believe were caused by the medication. Understanding your legal rights and options is important if you've used Depo-Provera and been diagnosed with a meningioma.
What Is a Meningioma?
A meningioma is a type of brain tumor that forms in the meninges, the protective membranes that surround the brain and spinal cord. While most meningiomas are benign, meaning they are not cancerous, they can still cause serious problems. These tumors can grow large enough to press against the brain, causing symptoms such as headaches, vision problems, seizures, and cognitive changes.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Meningiomas are typically diagnosed through imaging studies such as MRI or CT scans. In some cases, a biopsy may be performed to confirm the diagnosis. Treatment options vary depending on the size and location of the tumor, and may include monitoring, surgery, or radiation therapy.
The connection between meningiomas and hormone exposure has been the subject of scientific research for many years. Studies have found that meningiomas have receptors for certain hormones, including progestogens, which may explain why exposure to these hormones could promote tumor growth.
The Connection Between Depo-Provera and Meningiomas
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitDepo-Provera contains the hormone medroxyprogesterone acetate, which is a type of progestogen. Scientific research has identified a potential link between progestogen-containing medications like Depo-Provera and the development of meningiomas.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Studies have found that women who used progestogen-based contraceptives, including Depo-Provera, for extended periods may have an increased risk of developing meningiomas. The risk appears to be higher in women who used the medication for longer durations, suggesting a dose-response relationship. This means that the longer someone used Depo-Provera, the greater their potential risk.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The mechanism by which progestogens may contribute to meningioma development is not fully understood, but research suggests that these hormones may stimulate the growth of meningioma cells. Meningiomas have been found to have receptors for progestogen hormones, which may explain why exposure to these hormones could promote tumor growth.
Who May Qualify for a Depo-Provera Meningioma Lawsuit?
Women who may qualify for a Depo-Provera meningioma lawsuit typically share certain characteristics related to their medication use and medical diagnosis. Understanding these factors can help you determine whether you may have a valid claim.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewDuration of Use: Women who used Depo-Provera for extended periods, particularly five years or more, may have stronger cases. The risk of meningioma development appears to increase with longer duration of use, so those who received injections over many years may be more likely to qualify.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Meningioma Diagnosis: A confirmed diagnosis of meningioma is typically required. This diagnosis is usually made through imaging studies such as MRI or CT scans, and may be confirmed through biopsy if surgery is performed. The diagnosis should have occurred after a period of Depo-Provera use.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Timing of Diagnosis: The timing between Depo-Provera use and meningioma diagnosis is important. Cases where the diagnosis occurred during or after Depo-Provera use may be more relevant than cases where the diagnosis occurred many years before starting the medication.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityAccording to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Medical Documentation: Having medical records that document both your Depo-Provera use history and your meningioma diagnosis is important. These records help establish the connection between the medication and your condition.
If you've used Depo-Provera and received a meningioma diagnosis, you may want to learn whether you qualify for a free case review. This initial evaluation can help determine whether your situation may meet the criteria for pursuing a legal claim.
Current Status of Depo-Provera Meningioma Litigation
Litigation related to Depo-Provera and meningiomas is developing as more women learn about the potential connection between their medication use and brain tumor diagnosis. Cases are being filed alleging that manufacturers knew about the risks but failed to adequately warn patients and healthcare providers.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The litigation is in early stages, with cases being filed in various courts. As more scientific evidence emerges and more women come forward, the litigation may develop into consolidated proceedings similar to other pharmaceutical mass tort cases. Scientific evidence continues to accumulate linking progestogen exposure to meningioma development, and this evidence may support legal claims that manufacturers had an obligation to warn about these risks but failed to do so adequately.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationAccording to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Evidence suggests that the risks associated with progestogen exposure were known for years before adequate warnings were provided. Pharmaceutical companies have a legal obligation to warn patients and healthcare providers about known risks. If you've used Depo-Provera for an extended period and developed a meningioma, you may be entitled to compensation for medical expenses, lost wages, pain and suffering, future medical care, and reduced quality of life.
Common Symptoms of Meningiomas
Meningiomas can cause a variety of symptoms depending on their size and location. Understanding these symptoms can help you recognize potential warning signs and seek appropriate medical care.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Headaches: Persistent or worsening headaches are one of the most common symptoms of meningiomas. These headaches may be different from typical headaches and may worsen over time.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Vision Problems: Meningiomas located near the optic nerve or other visual pathways can cause vision changes, including blurred vision, double vision, or loss of vision in one or both eyes.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Seizures: Some meningiomas can cause seizures, particularly if they're located in areas of the brain that control motor function or consciousness.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Cognitive Changes: Meningiomas may cause changes in memory, concentration, or other cognitive functions, especially if they're large or located in areas that affect brain function.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Weakness or Numbness: Depending on the location of the tumor, meningiomas can cause weakness or numbness in various parts of the body.
Hearing Loss: Meningiomas located near the auditory nerve can cause hearing loss or ringing in the ears.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewIt's important to note that these symptoms can have many causes, and having these symptoms doesn't necessarily mean you have a meningioma. However, if you've used Depo-Provera and are experiencing any of these symptoms, it's important to discuss them with your healthcare provider and consider whether imaging studies may be appropriate.
What a Case Review Involves
A case review is an initial evaluation to determine whether you may have a valid legal claim related to Depo-Provera use and meningioma development. This process is confidential, free, and does not create any obligation on your part.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Initial Consultation: The process typically begins with a conversation about your Depo-Provera use history and medical diagnosis. You'll be asked about when you started using Depo-Provera, how long you used it, when you received your meningioma diagnosis, and what symptoms you've experienced.
Medical Records Review: If you decide to proceed, medical records related to your meningioma diagnosis and treatment may be reviewed. This helps establish the connection between your medication use and your condition.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityA 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Eligibility Assessment: Based on the information gathered, an assessment will be made about whether you may qualify to pursue a claim. Factors considered include the duration of your Depo-Provera use, the timing of your diagnosis, and how your case fits within the broader litigation.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Next Steps: If you may qualify, you'll be informed about the next steps in the legal process. This might include connecting you with an independent law firm that handles Depo-Provera cases.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The case review process is designed to be straightforward and respectful of your situation. The goal is to help you understand your options and determine whether pursuing legal action makes sense for your circumstances. If you're ready to begin, you can contact us for a free case review.
No outcome guarantees
Top Tier Legal, LLC connects you with independent firms for evaluation only. Even strong science does not ensure compensation; eligibility and damages depend on your specific facts.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Scientific Evidence: While research suggests a link between Depo-Provera and meningiomas, scientific evidence continues to evolve. Courts will evaluate this evidence, and outcomes may depend on how juries and judges interpret the available research.
See if you qualify for a free case review to learn more about your potential rights and options. You can also learn more about Depo-Provera lawsuit information and your potential rights.
Frequently Asked Questions
- Q: What is a meningioma?
- A meningioma is a type of brain tumor that forms in the meninges, the protective membranes surrounding the brain and spinal cord. While most meningiomas are benign, they can grow large enough to cause symptoms and may require treatment, including surgery.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
- Q: How is the connection between Depo-Provera and meningiomas established?
- Scientific research has identified a potential link between progestogen-containing medications like Depo-Provera and meningioma development. Studies have found that women who used these medications for extended periods may have an increased risk.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
- Q: Do I need to have had surgery to qualify for a lawsuit?
- A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Surgery is not necessarily required to qualify for a lawsuit. Cases are evaluated based on individual circumstances, including the size and location of the meningioma, symptoms experienced, and treatment received or recommended.
- Q: How long do I have to file a Depo-Provera meningioma lawsuit?
- Statutes of limitations vary by state and depend on factors such as when you discovered your injury and when you were diagnosed. It's important to act promptly if you believe you may have a claim.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewAccording to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
- Q: What compensation might I be entitled to?
- Compensation amounts vary significantly based on individual circumstances, including the severity of your condition, medical expenses, lost wages, and other factors. Past results don't guarantee future outcomes.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
- Q: Can I still qualify if I used Depo-Provera many years ago?
- The timing of your Depo-Provera use and meningioma diagnosis is important, but there's no specific time limit that automatically disqualifies a case. Each situation is evaluated individually.
- Q: What should I do if I've been diagnosed with a meningioma after using Depo-Provera?
- If you've been diagnosed with a meningioma after using Depo-Provera, you may want to consider a free case review to determine whether you may qualify for a lawsuit. It's also important to continue working with your healthcare providers to manage your condition.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityImportant Disclaimers
Understanding your legal options related to Depo-Provera meningioma lawsuits is an important first step for women who have used the medication and been diagnosed with meningiomas. If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, understanding your legal rights and options is important.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Evidence such as imaging reports, employment records, and prescribing history often drives eligibility. Gather what you have before your review to speed intake.
Top Tier Legal, LLC is not a law firm and does not provide legal advice. This content is for informational purposes only. Submitting information does not create an attorney-client relationship. If you qualify, Top Tier Legal, LLC may connect you with an independent law firm. Past results do not guarantee future outcomes.
